Lindsay Good
Family · Jenkintown, PANPI 1952681637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 409 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $3,354 and has fallen 79.7% since, to $682 in 2025. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 409 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Abbott$837
- Novo Nordisk$759
- Lilly USA, LLC$668
- AstraZeneca$360
- Sanofi-aventis U.S. LLC$350
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,418100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,363 |
| Abbott | 26 | $837 |
| Novo Nordisk | 44 | $759 |
| Lilly USA, LLC | 34 | $668 |
| AstraZeneca | 24 | $360 |
| Sanofi-aventis U.S. LLC | 19 | $350 |
| Paratek Pharmaceuticals, Inc. | 19 | $348 |
| Boehringer Ingelheim | 15 | $270 |
| GSK | 12 | $261 |
| Merck | 13 | $222 |
| Bayer | 12 | $214 |
| Johnson & Johnson | 12 | $208 |
| Teva Pharmaceuticals USA, Inc. | 12 | $191 |
| Gilead | 8 | $174 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $166 |
| Amarin Pharma, Inc. | 10 | $151 |
| Idorsia Pharmaceuticals US Inc | 1 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $118 |
| Astellas Pharma US Inc | 7 | $100 |
| Biohaven Pharmaceuticals, Inc. | 4 | $88 |
| Kowa Pharmaceuticals America, Inc. | 5 | $81 |
| UCB, Inc. | 3 | $70 |
| Hikma Pharmaceuticals USA | 5 | $69 |
| Eyevance Pharmaceuticals LLC | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $36 |
| Amgen | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Philips North America LLC | 2 | $23 |
| Eisai Inc. | 1 | $23 |
| Boston Scientific | 1 | $20 |
| Pfizer | 1 | $18 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$333
- TRELEGY ELLIPTA$121
- QUVIVIQ$120
How this compares
$7,418 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $33,016 |
| JardianceEmpagliflozin | 26 | $30,501 |
| EliquisApixaban | 26 | $22,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $19,484 |
| EntrestoSacubitril/Valsartan | 17 | $19,316 |
| MounjaroTirzepatide | 14 | $14,344 |
| TrulicityDulaglutide | 15 | $13,962 |
| FarxigaDapagliflozin Propanediol | 15 | $12,766 |
| MyrbetriqMirabegron | 16 | $12,040 |
| Lidocaine | 33 | $4,605 |
| VascepaIcosapent Ethyl | 15 | $4,181 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $3,298 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $2,735 |
| Atorvastatin Calcium | 128 | $1,844 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 29 | $1,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $759 | $33,01627 claims |
| Boehringer IngelheimJardiance | $270 | $30,50126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $668 | $28,30729 claims |
| PfizerEliquis | $18 | $22,82126 claims |
| GSKTrelegy Ellipta | $261 | $19,48424 claims |
| NovartisEntresto | $15 | $19,31617 claims |
| AstraZenecaFarxiga | $360 | $12,76615 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $12,04016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Jenkintown
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.